The latest news on tucatinib (tucatinib) targeted drugs: indications, efficacy and marketing status

Tucatinib (Tucatinib) is an oral, small-molecule tyrosine kinase inhibitor that targets HER2 (human epidermal growth factor receptor 2). It is often used in combination with other drugs to treat HER2-positive advanced or metastatic breast cancer, especially those with brain metastases. Tucatinib helps delay tumor progression and improve patient survival rates by highly selectively inhibiting the HER2 signaling pathway. Its clinical efficacy has been verified in multiple international studies.

In terms of indications, tucatinib is mainly used for breast cancer patients who have progressed after receiving multiple anti-HER2 treatments. It especially shows unique advantages for patients with brain metastases. Studies have shown that tucatinib combined with other anti-cancer drugs can significantly prolong progression-free survival (PFS) and overall survival (OS), and also has strong control over metastases in the central nervous system.

At present, the original drug of tucatinib has not been officially sold in the Chinese market, so it cannot be included in the medical insurance system. In the European market, 150mg84 original drug may be sold for more than 40,000 yuan, which is expensive. In overseas markets, generic drugs of tucatinib have been launched, such as the 150 mg 60 tablet product produced by a Lao pharmaceutical factory, which sells for about more than 2,000 yuan. Compared with the original drug, the price is more affordable, and the ingredients of the generic drug are basically the same as the original drug, providing patients with a more economical treatment option. With the acceleration of global drug access, tucatinib is expected to enter the domestic market and benefit more patients in the future.

Reference materials:https://www.tukysa.com/